
    
      This was a multi-center, prospective, post-marketing observational study of participants with
      severe chronic plaque psoriasis who began adalimumab therapy in the United Kingdom. Although
      153 participants enrolled in the study, data was only analyzed on 143 individuals and there
      were no interventions or changes to participant management for the study. Prior to initiating
      adalimumab therapy (baseline), the Dermatology Life Quality Index (DLQI), Self-Administered
      Psoriasis Area Severity Index (SAPASI), Hospital Anxiety and Depression Scale (HADS),
      Cutaneous Body Image (CBI) scale, Short Form 12 (SF-12) Health Survey, Female Sexual Function
      Index (FSFI) (female participants) and International Index of Erectile Function (IIEF) (male
      participants) questionnaires were completed by participants and at 4 weeks, 16 weeks and 6
      months following initiation.
    
  